Rociletinib

Rociletinib
Clinical data
Other names	CO-1686, AVL-301
Routes of; administration	By mouth
ATC code	L01XE37 (WHO) ;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-(3-{[2-{[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)-4-pyrimidinyl]amino}phenyl)acrylamide;
CAS Number	1374640-70-6;
PubChem CID	57335384;
ChemSpider	30646712;
UNII	72AH61702G;
KEGG	D10858;
CompTox Dashboard (EPA)	DTXSID801025958 ;
Chemical and physical data
Formula	C27H28F3N7O3
Molar mass	555.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F;
	InChI InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35); Key:HUFOZJXAKZVRNJ-UHFFFAOYSA-N;

Rociletinib (INN) is a drug for the treatment of non-small cell lung cancer, acting as an inhibitor of the epidermal growth factor receptor (EGFR).^[1] It was being developed by Clovis Oncology.^[2] According to the company web site as of November 2016, development was halted and studies on the drug are no longer accepting new patients, but Clovis will continue to supply the drug to patients whose physicians had recommended continued treatment.^[3]

References

^ Van Der Steen, Nele; Caparello, Chiara; Rolfo, Christian; Pauwels, Patrick; Peters, Godefridus; Giovannetti, Elisa (2016). "New developments in the management of non-small-cell lung cancer, focus on rociletinib: What went wrong?". OncoTargets and Therapy. 9: 6065. doi:10.2147/OTT.S97644. PMC 5063481. PMID 27785053.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. 2015-11-16. Retrieved 2016-01-04.
^ "About Clovis". Retrieved 18 November 2016.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Van Der Steen, Nele; Caparello, Chiara; Rolfo, Christian; Pauwels, Patrick; Peters, Godefridus; Giovannetti, Elisa (2016). "New developments in the management of non-small-cell lung cancer, focus on rociletinib: What went wrong?". OncoTargets and Therapy. 9: 6065. doi:10.2147/OTT.S97644. PMC 5063481. PMID 27785053.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[OncLive_2015-2] "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. 2015-11-16. Retrieved 2016-01-04.

[3] "About Clovis". Retrieved 18 November 2016.

[1]

[2]

[3]